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ABSTRACT
JDP2 is a ubiquitously expressed bZIP repressor
protein. JDP2 binds TPA response element and
cyclic AMP response element located within various
promoters. JDP2 displays a high degree of homol-
ogy to the immediate early gene ATF3. ATF3 plays
a crucial role in the cellular adaptive response to
multiple stress insults as well as growth stimuli.
We have identified ATF3 as a potential target gene
for JDP2 repression. JDP2 regulates the ATF3 pro-
moter potentially through binding to both the con-
sensus ATF/CRE site and a non-consensus ATF3
auto-repression DNA-binding element. Expression
of ATF3 protein in wild-type mouse embryo fibro-
blast (MEF) cells is below the detectable levels,
whereas, JDP2 disrupted MEF cells display notice-
able level of ATF3 protein. Following either serum
or ER stress stimulation, ATF3 expression is poten-
tiated in JDP2-KO fibroblast cells as compared
with wild-type cells. Mice with either JDP2 over-
expression or JDP2 disruption display undetectable
level of ATF3 protein. However, ATF3 induction in
response to either growth or stress signals is
dependent on JDP2 expression level. ATF3 induc-
tion is attenuated in JDP2 over-expressing mice
whereas is potentiated in JDP2-KO mice as com-
pared with the corresponding wild-type mice.
Collectively, the data presented strongly suggest
that JDP2 plays a role in the determination of the
ATF3 adaptive cellular threshold response to differ-
ent stress insults and growth stimuli.
INTRODUCTION
c-Jun dimerization protein 2 (JDP2) is a bona ﬁde member
of the AP-1 family that was isolated because of its ability
to interact with c-Jun (1) and ATF2 (2). JDP2 encodes an
18kDa protein that is able to homodimerize, as well as to
form heterodimers with other AP-1 members, such as
c-Jun, JunB, JunD and ATF2, and members of the C/EBP
family, C/EBPg (3) and CHOP10 (4) and more recently,
IRF2-binding protein (5). Dimerization occurs through
a conserved leucine zipper domain found in all members
of the AP-1 family. A basic domain located adjacent to the
leucine zipper dimerization motif is responsible for the
direct association with TRE as well as CRE DNA-binding
sequences. JDP2 is a repressor of AP-1 protein family (1).
The mechanism by which JDP2 represses AP-1 transcrip-
tion involves competition for DNA binding (1), inactive
heterodimer formation (1), indirect recruitment of histone
deacetylase 3 (6), nucleosome assembly activity (7), inhi-
bition of histone acetylation (7), and potential competition
with JNK phosphorylation (8). JDP2 has been shown to
play a role in the cellular diﬀerentiation of skeletal muscle
(9), osteoclasts (10), adipocytes (11) and F9 cells (6).
JDP2 is most closely related to ATF3, a member of the
ATF/CREB (CRE-binding protein), which is a subfamily
of the AP-1 group (12). ATF3 is a stress inducible gene, as
its mRNA level greatly increases upon exposure of cells
to stress signals (12). ATF3 has been reported to activate
transcription as a heterodimer with c-Jun, whereas it
represses transcription as a homodimer (13). Both ATF3
and JDP2 are able to dimerize with CHOP10, which
is a member of the C/EBP family. Whereas the
JDP2-CHOP10 heterodimer forms a non-functional com-
plex with CRE containing promoters, it strongly
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(4). JDP2 and ATF3 exhibit 61% overall homology. The
bZIP domains of these two proteins share 90% homology,
whereas, beyond the bZIP domain, JDP2 and ATF3 dis-
play very low similarity. Both JDP2 and ATF3 bind to
TRE as well as to CRE DNA elements in vitro. It has
recently been shown in our laboratory that transgenic
mice with temporal cardiac expression of JDP2 exhibit a
similar phenotype to ATF3 transgenic mice. This may
suggest that these two proteins play a similar role in the
heart (14,15). Despite the high degree of similarity in this
aspect, it seems that there are considerable diﬀerences
between JDP2 and ATF3 with regard to their transcrip-
tion regulation. JDP2 is ubiquitously expressed and its
level remains unchanged following various stimuli (8).
Nevertheless, in a number of processes, such as diﬀerenti-
ation of skeletal muscle cells (9) and osteoclasts (10), and
ultraviolet irradiation (16), a modest increase in JDP2
expression is observed. JDP2 undergoes phosphorylation
by c-Jun N-terminal kinase (JNK) and p38 kinase on
threonine 148, but the precise role of this phosphorylation
in terms of its biological function is currently unknown
(8,17). Diﬀerent studies suggest that JDP2 has a dual role
in malignant transformation. On the one hand, it is well
established that JDP2 eﬃciently counteracts AP-1 tran-
scription (1), and thus may interfere with the oncogenic
properties of c-Jun. JDP2 has been found to inhibit cell
transformation induced by Ras in vitro and in prostate
cancer cell line xenografts injected into SCID mice (18).
On the other hand, JDP2 has been identiﬁed as a candi-
date oncogene in a high-throughput screen based on viral
insertional mutagenesis in wild-type mice (19). It has
also been associated with acceleration of multicentric
lymphoma development, in collaboration with a loss of
function mutation of the cell cycle inhibitor, p27, (20)
and with the over-expression of c-Myc and Runx2 onco-
genes (21).
In the present study, we identiﬁed ATF3 as a JDP2
target gene. In HeLa and MEF cells, JDP2 regulates
ATF3 transcription by binding to the ATF3 promoter
region involved in its auto-repression. In addition,
JDP2 over-expression in mice results in attenuation of
ATF3 expression in various model systems. Consistently,
ablation of JDP2 expression results in the potentiation
of the ATF3 expression in response to various signals
both in vitro and in vivo. Collectively, JDP2 plays
a role in the determination of the cellular adaptive
response of the ATF3 expression level to various cellular
stimuli.
MATERIALS AND METHODS
Plasmids
pcDNA-JDP2 and pcDNA-VP16-JDP2 are mammalian
expression plasmids encoding the wild-type JDP2 or
JDP2 transcription activator, respectively. pGL2 basic
luciferase reporter plasmid (Promega Inc.) was used to
insert KpnI-XhoI fragments derived from the  1350 to
+22 ATF3 promoter as indicated. The primers used in
this study are shown (sequences corresponding to the
human ATF3 promoter are underlined):
 1350 KpnI top
50-CGGGGTACCGTCATCCACGGGAGTAAGAA
 926 KpnI top
50-GGGGTACCTCCTGGACTCCGATCTTTTC
 390 KpnI top
50-GCGGGGTACCCAGCGCGGTGGAGTCA
 138 KpnI top
50-CGGGGTACCTCCTCCGCTCCGTTCGG
+22 XhoI Bott
50-CCGCTCGAGCGCGCCTGGCTGCGT
Celllines
HeLa stable cell lines were generated by retroviral infec-
tions as described in (18). Following retroviral infections,
puromycin resistant HeLa cells were pooled and used
in all experiments. Transient transfections were carried
out with JetPei reagent (PolyPlus transfection Inc.)
according to the manufacturer’s instructions. SV40 large
T-antigen immortalized MEF cells were established from
12–14 days mice embryo of C57BL/6 background of either
wild-type or JDP2 disrupted allele.
Reporter assay
Luciferase reporter assays were performed with luciferase
kit (Promega Inc.) according to the manufacturer’s
instructions.
Cellular treatments
HeLa and MEF cells were serum starved 0.1% for 16h;
thereafter 20% serum was added for 1h. Nuclear extracts
were prepared as previously described (4). Exponentially
growing MEF cells were treated with 1mM thapsigargin
in 10% serum for the indicated time.
RT–PCR
Semi-quantitative RT–PCR was performed using Verso
cDNA kit (Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions.
The following primers were used:
human-ATF3-F 50-ATGATGCTTCAACACCCAGGC
human-ATF3-R 50-TTAGCTCTGCAATGTTCCTTC
human-GSG1-F 50-ATGGCCAAGATGGAGCTCTCG
human-GSG1-R 50-CTCCCCTGGTTCTTCCACAGT
human-GAPDH-F 50-CATCACCATCTTCCAGGAGCGA
human-GAPDH-R 50-GTCTTCTGGGTGGCAGTGATGG
Microarray
RNA extraction. Total RNA was isolated from an expo-
nentially growing HeLa stable cell line and was prepared
using TRI reagent solution (Sigma Chemicals Ltd). Cell
lines represent vector, JDP2 and VP16-JDP2 expressing
cells. RNA quality and integrity were determined using
the Eukaryote Total RNA Nano 6000 assay (Agilent
RNA 6000 Nano LabChip Kit, part number 5065–4476)
on the Agilent Technologies 2100 Bioanalyzer, and
quantiﬁed by measuring A260nm on a nanodrop
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Rockland, DE).
Generation of fluorescently labeled cRNA targets. Total
RNA isolated was ampliﬁed and ﬂuorescently labeled
using the Agilent Technologies Low Input Linear
Ampliﬁcation Kit (part number 5184-3523) following
the protocol described in the kit manual. The labeled
cRNA was puriﬁed using Qiagen’s RNeasy Kit (part
number 74104).
Hybridization and scanning of microarrays. RNA samples
were prepared from two biological replicate experiments
for HeLa-JDP2 and HeLa-VP16-JDP2 to form technical
replicates with the control HeLa vector cell line. For each
hybridization, 750ng of cyanine 3- and 750ng of cyanine
5-labeled cRNA were fragmented and hybridized to
an Agilent Technologies Whole Human Genome
oligo Microarray (part number G4112F), using the
Agilent Gene Expression hybridization kit (cat.
number 5188–5242), as described in the manual.
Following hybridization, all microarrays were washed
and scanned using Agilent’s dual laser G2505B microarray
scanner. The data were then extracted from images by
using Feature Extraction 9.5 software (Agilent
Technologies).
Data analysis. The data from all arrays were analyzed
using GeneSpring GX software (Agilent Technologies
UK Limited, South Queensferry, UK).
Array normalization was done using the intensity-
dependent Lowess normalization method. Analysis was
performed on the log expression ratios that were produced
in the normalization step. Biological replicates were trea-
ted as duplicate measurements, and their averages were
calculated. Features that ﬂagged absent in all the arrays
and non-reliable features with a very low signal (<50 in
both channels) were removed prior to further analysis.
The normalized data were analyzed to identify genes
whose expression appeared to be up- or down-regulated
by an arbitrary cut oﬀ of at least 2-fold.
Electrophoretic mobility shift assay(EMSA)
EMSA was performed with bacterially puriﬁed His-JDP2
as described in (1). The following
32P-end-labeled DNA
probes were used:
CRE 50 TCGATTGGCTGACGTCAGAGAGAG
 20wt. 50 AAGGGGTGATGCAACGCTCTCCAAGCCACA
 20 mut 50 AAGGGGACCTGCAACGCTCTCCAAGCCACA
Chromatin immunoprecipitation (ChIP)
ChIP was performed using a ChIP assay kit (Upstate tech-
nologies) according to the manufacturer’s instructions.
PCR cycle was performed with an annealing temperature
of 588C and 32 cycles to obtain a signal in the linear range.
The following oligonucleotides derived from the ATF3
promoter were used to amplify the corresponding genomic
region. Numbers represent bp distance upstream ( )o r
downstream (+) from the ATF3 transcription start site
according to (22).
Primers used for ChIP derived from the human ATF3
promoter:
ChIP-209-F 50-CCGAACTTGCATCACCAGTGC
ChIP+34-R 50-GAGCTGTGCAGTGCGCGCC
ChIP -928-F 50-CCTCCTGGACTCCGATCTTTTC
ChIP -674-R 50-TGCGGCGGGGACCGAGAA
Primers used for ChIP derived from the mouse ATF3
promoter:
ChIP-246-F 50- GTCCCGGGCGTGCGAGGAA
ChIP+25-R 50- GCGCGGCGTCTCGCTGAGTG
Western blot analyses
Western blot analyses were performed with 5% dry milk
in PBS. The primary antibodies used were rabbit polyclo-
nal ATF3 (C-19, Santa Cruz), rabbit polyclonal anti-cJun
(H-79, Santa Cruz), rabbit polyclonal anti-GAPDH
(FL-335, Santa Cruz), mouse monoclonal anti a-tubulin
(T-9026, Sigma Aldrich), and rabbit polyclonal anti-
JDP2 (1).
Transgenic mice
All studies involving mice were regulated under the pro-
tocol approved by the Technion Animal Inspection
Committee. The Technion holds an NIH animal approval
license number A5026-01. The following mice lines were
used in this study: Tet-JDP2 transgenic responder line,
MHCa-tTA cardiomyocytes driver line, LAP-tTA liver
driver line, C57BL/6 wild-type mice and C57BL/6
JDP2-KO mice.
Angiotensin treatments
Mice with the indicated genotype were injected intraper-
itoneally with either angiotensin II 1.5mg/Kg or isopro-
terenol 2.5mg/kg. Saline was used as the vehicle. Two
hours following injection the mice hearts were harvested
in RIPA buﬀer and subjected to SDS–PAGE followed by
western blot analysis.
CCl4treatments
Mice were injected intraperitoneally with 0.5 ml/Kg CCl4
diluted in olive oil. Livers were harvested at the indicated
time points and nuclear extract was subjected to SDS–
PAGE followed by western blot analysis.
RESULTS
ATF3 isaJDP2 target gene
JDP2 is a well established bZIP repressor protein binding
to either TPA or CRE DNA response elements. JDP2 can
be turned into a transcription activator by fusing JDP2 to
a strong activation domain derived from the herpes sim-
plex virus protein VP16 (4). To identify JDP2 direct target
genes, HeLa cell lines with ectopic expression of either
JDP2 or VP16-JDP2 were established. We hypothesized
that the transcription of a JDP2 target gene would be
repressed in the JDP2 expressing cell line but potentiated
in the VP16-JDP2 expressing cell line. To study the expres-
sion proﬁle of the diﬀerent HeLa cell lines, mRNA was
extracted and was used as a template to generate
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derived microarrays. cRNA derived from HeLa vector
control cell line was used as a gene expression proﬁle
reference. A JDP2 candidate target gene was considered,
if it displayed a diﬀerential expression of at least 2-fold
repression and 2-fold activation with samples derived
from either JDP2 or VP16-JDP2 expressing cells, respec-
tively. Only three genes fulﬁlled this criterion: PCDH7,
ATF3 and GSG1 (Figure 1A). To validate the microarray
results, primers were designed to amplify the correspond-
ing cDNA derived from the diﬀerent HeLa cell lines.
Consistent with the microarray data, both GSG1 and
ATF3 displayed a reduced transcription in the HeLa-
JDP2 cell line and a higher transcription in the
VP16-JDP2 cell line (Figure 1B). In contrast, the
PCDH7 transcription was found at similar levels irrespec-
tive of JDP2 expression (data not shown). GSG1 is a
germ-cell-associated protein with an unknown function.
The role of JDP2 in GSG1 regulation was not further
pursued. Here, we further studied the role of JDP2 in
ATF3 transcription regulation. ATF3 and JDP2 proteins
are highly homologous in function (4,14) but diﬀer mainly
in their mode of regulation. While JDP2 is ubiquitously
expressed (8), ATF3 is considered an immediate early
gene. ATF3 protein expression is highly induced in
response to various cell stresses and cellular signals (23).
ATF3 proteinlevel is dependenton JDP2 function
We ﬁrst sought to verify that JDP2 regulation of ATF3
transcription observed at the mRNA level also reﬂects a
change in ATF3 protein expression level. The diﬀerent
HeLa cell lines were cultured in three diﬀerent growth
conditions representing exponentially growing cells
(10% serum), serum starved cells (0.1% serum) and
serum induced cells (20% serum). Nuclear cell lysate was
subjected to SDS–PAGE and western blotting with anti-
ATF3 antibody (Figure 1C, top panel). Whereas HeLa-
vector control cells displayed a basal level of ATF3
protein, the HeLa-JDP2 expressing cell line exhibited
a dramatically reduced ATF3 protein expression level.
In contrast, high level of ATF3 protein was observed
in lysate derived from HeLa-VP16-JDP2 cell line
(Figure 1C, top panel). The diﬀerential expression proﬁle
was observed in cell lysate derived from cells grown in all
three growth conditions examined. The expression level of
the housekeeping gene a-tubulin conﬁrmed similar protein
lysate loadings (Figure 1C, bottom panel). In addition,
the expression level of the ectopically expressed JDP2,
VP16-JDP2, as well as the endogenous JDP2 expression
level, is shown (Figure 1C, middle panel). Collectively,
ATF3 protein expression levels present in the diﬀerent
HeLa cell lines are consistent with the changes observed
at the transcriptional level. Thus, ATF3 expression is
repressed in the presence of over-expression of JDP2,
whereas it is induced following ectopic expression of the
JDP2 transcriptional activator mutant.
Identifying JDP2 DNA responsive elements within the
ATF3promoter
We sought to map the JDP2 potential DNA-binding
sequences within the human ATF3 promoter that are
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Figure 1. ATF3 is a JDP2 target gene in HeLa cells. (A) cDNA derived from HeLa cell lines with ectopic expression of either dominant active
JDP2 (VP16-JDP2) or wild-type JDP2 (JDP2) was used to probe 4X44K microarray in duplicate. Average fold expression is determined relative to
cDNA derived from HeLa-vector cell line. Genes displaying at least 2-fold reduced levels in HeLa-JDP2 cell line and a 2-fold increased level in
HeLa-VP16-JDP2 cells are shown. Genebank accession number as well as gene annotation is indicated. (B) Validation of microarray results by
RT–PCR. cDNA was prepared from mRNA derived from the indicated cell lines and was used as a template for semi quantitative RT–PCR. No
cDNA was used for PCR control ( ). ATF3 and GSG1 PCR reactions were performed in the presence of a trace amount of a
32P-dCTP. PCR
reactions were separated on non-denaturing 10% PAGE dried and exposed to autoradiography (top and middle panel). The housekeeping gene
GAPDH RT–PCR reaction was separated on 1.5% agarose gel followed by ethidium bromide staining and visualized by UV light (bottom panel).
(C) Western blot analysis of nuclear extracts derived from the indicated HeLa cell lines grown in low serum (0.1% serum lanes 1–3), exponentially
growing cells (10% serum, lanes 4–6) and cells induced with 20% serum for 1h (lanes 7–9). Nuclear extract (50mg) were separated on 12.5% SDS–
PAGE transferred to nitrocellulose membrane and probed with anti-ATF3, anti-JDP2 and a-tubulin (loading control).
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repression. To this end, we used reporter gene assays
in HeLa cells. Since JDP2 strongly represses the empty
PGL2-promoter luciferase reporter plasmid containing
the simian virus 40 minimal early promoter (data not
shown), the PGL2-basic reporter plasmid (Promega Inc.)
was used. This plasmid harbors neither the promoter nor
TATA element upstream of the luciferase gene (Figure 2).
A fragment which consists of  1350 to +22bp, relative to
the ATF3 transcription start site, was designed to drive
the expression of the luciferase reporter gene. This region
contains multiple TRE and CRE potential consensus
binding sites and a functional TATA element (22). HeLa
cells were co-transfected with the luciferase reporter plas-
mid together with a JDP2 expression plasmid. Luciferase
activity was determined 24h following transfection.
Indeed, JDP2 was able to repress signiﬁcantly the lucifer-
ase reporter activity by 6–7 folds, relative to the luciferase
reporter activity obtained in the absence of JDP2. To fur-
ther map the JDP2 responsive elements within the ATF3
promoter, a series of 50 deletions of the promoter were
designed (Figure 2). Each deleted mutant removed
between two to three potential TRE or CRE consensus
DNA elements and resulted in a reduced transcription
relative to the longest ATF3 promoter fragment consisting
of  1350bp upstream to the transcription start site
(Figure 2). Subsequently, the ability of JDP2 to repress
the activity of the ATF3 promoter deleted mutants was
examined in co-transfection experiments in HeLa cells. A
promoter fragment, consisting of  138bp to +22,
derived from the ATF3 promoter, resulted in JDP2 repres-
sion activity similar to that obtained with the longest
ATF3 promoter fragment (Figure 2). The remaining
ATF3 promoter sequence ( 138 till +22) consists of a
consensus ATF/CRE site located at  90bp as well as an
ATF3 non-canonical auto-repression site located at
 20bp (22). To delineate which of these DNA-binding
elements is responsible for ATF3 repression by JDP2,
a luciferase reporter construct harboring a mutated
 20-binding element ( 138-20) was designed. The abil-
ity of JDP2 to repress the transcription of the mutated
ATF3 promoter reporter plasmid was examined in HeLa
cells. Although JDP2 was able to repress modestly
the ATF3 reporter ( 138-20), the repression level
was only about 50%, in comparison with the wild-type
construct (Figure 2). Once the  90 ATF/CRE site
was mutated along with the  20 site, JDP2 repression
was completely lost (Figure 2,  138both). This
result indicates that JDP2 is able to repress ATF3 trans-
cription via both the consensus ATF/CRE site and the
ATF3 auto-repression element located at  90 and  20,
respectively.
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Figure 2. Mapping JDP2 repression activity within the ATF3 promoter. Schematic representation of the ATF3 promoter deletion mutants used.
DNA fragments were subcloned upstream of the luciferase gene in the PGL2 basic luciferase reporter plasmid. The number on the left side of each
construct represents the percentage of transcription activity obtained with the corresponding promoter fragment relative to the transcription activity
obtained with the longest ATF3 fragment used (taken as 100%). The numbers at the top of each depicted construct correspond to the promoter
length (bp) upstream ( ) or downstream (+) in respect to the human ATF3 transcription start site. The position of the ATF3 promoter harboring
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JDP2 expression vector. Luciferase activity was measured 24h following transfection. Fold repression was calculated by dividing the luciferase
activity obtained with the pcDNA empty expression vector to the luciferase activity obtained in the presence of JDP2 expression plasmid. The results
represent the average and SEM of four independent experiments.
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sites invitro and invivo
Since the DNA element located at  20 is a non-canonical
ATF/CRE site, we examined whether or not bacterially
puriﬁed His-JDP2 protein is able to bind the  20 site
using an electrophoretic mobility shift assay (EMSA).
Indeed, bacterially puriﬁed His-JDP2 protein displayed
strong binding to labeled CRE and the  20 DNA
sequence elements but failed to associate with the labeled
mutated  20 DNA-binding site (Figure 3A).
To examine further whether or not JDP2 is associated
with the ATF3 promoter in vivo, we used chromatin
immunoprecipitation (ChIP) in HeLa-JDP2 cell line.
Cells were cross-linked with formaldehyde and the
DNA was fragmented to 500–1000bp by sonication.
Immunoprecipitation was performed with either non-rele-
vant serum (anti-thiamine transporter 1, THTR1) or with
anti-JDP2 polyclonal antibodies. Following extensive
washes, cross-linking was reversed and DNA was
extracted. The precipitated puriﬁed DNA was used as a
template for a PCR reaction with appropriate primers
located at  209 to +34 within the human ATF3 promo-
ter. As a control, we used PCR primers located at  928 to
 674 within the ATF3 promoter. This region was found
to be not associated with JDP2 repression activity.
Whereas following 32 PCR cycles no fragment was
detected with non-relevant serum, a speciﬁc ampliﬁed
DNA fragment of the expected size (243bp) was observed
with DNA lysate derived from anti-JDP2 precipitate
(Figure 3B). In addition, no speciﬁc ampliﬁcation was
observed using the control primers corresponding to
ATF3 promoter located between  674 and  928
(Figure 3B). Since the sites located at  90 and  20 are
in close proximity, it is impossible to resolve further the
association of JDP2 with either or both of them in vivo
using the ChIP assay. Collectively, these results strongly
suggest that JDP2 regulates ATF3 promoter via direct
association with ATF/CRE and the non-canonical site
located at  90 and  20bp, relative to the ATF3 transcrip-
tion initiation start site. The association of JDP2 with
these sequences is demonstrated both in vitro and in vivo.
JDP2expression level mediates ATF3expression level
The role of JDP2 in determining ATF3 basal expression
level was demonstrated so far in HeLa cell line with
ectopic expression of either wild-type JDP2 or the JDP2
transcriptional activator mutant (VP16-JDP2). To exam-
ine whether or not loss of JDP2 expression aﬀects ATF3
expression level, we took advantage of a mouse embryo
ﬁbroblast (MEF) cell line derived from mice harboring
homozygous JDP2 disrupted alleles (11). Whereas,
ATF3 expression is below the detectable level in nuclear
cell lysate derived from exponentially growing wild-type
MEF (Figure 4, top panel, lane 1), lysate derived from
JDP2-KO MEF cells displayed low but detectable ATF3
expression (Figure 4A, top panel, lane 6). Moreover, upon
either serum induction (20% serum) or thapsigargin treat-
ment, cell lysate derived from JDP2-KO MEF resulted in
higher induction of ATF3 protein as compared with wild-
type MEF lysate (Figure 4A, top panel, compare lanes 2–5
with 7–10). The level of a tubulin loading control dis-
plays comparable to lower levels of expression in
JDP2-KO MEFs, suggesting that the diﬀerences observed
represent an under-estimate of the actual diﬀerences in
ATF3 protein level. Collectively, these results suggest
that JDP2 moderately alter ATF3 basal expression level
but mainly aﬀect the expression of ATF3 in response to
environmental changes.
We next examined the binding of the endogenous JDP2
to the ATF3 promoter in untreated and thapsigargin trea-
ted MEF cells using ChIP with anti-JDP2 antibodies
(Figure 4B). In untreated wild-type MEF cells, endogen-
ous JDP2 protein is found to be associated with the mouse
ATF3 promoter region corresponding to  246 to +25.
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appropriate primers corresponding to  209 till +34 and  674 till  928 (expected size 243bp and 254bp, respectively). PCR reaction with no added
template (control, lanes 3 and 7), The ampliﬁed precipitated genomic DNA fragments were separated on 2% agarose gel stained with ethidium
bromide and visualized by UV light.
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the level of ATF3 promoter bound to JDP2 is observed
(Figure 4B, lanes 2–3). To demonstrate the speciﬁcity
of the anti-JDP2 antibody, we performed ChIP with
JDP2-KO MEF cells. Indeed, in the absence of JDP2 pro-
tein, no ampliﬁcation of the ATF3 promoter fragment is
observed (Figure 4B, lanes 5–6).
JDP2mediates ATF3 response toangiotensin IIand
isoproterenol inthe heart
To examine whether or not JDP2 regulates ATF3 expres-
sion in vivo, we examined the ATF3 expression in trans-
genic mice with either ectopic or knockout expression
of JDP2. Previously we have shown that intraperitoneal
injection of angiotensin II into mice highly induces ATF3
expression in the heart. We used the JDP2 transgenic
responder mice strain with temporal expression of JDP2
based on the tet-oﬀ transgenic system (24). Upon crossing
of the JDP2-responder mice with MHCa tetracycline acti-
vator driver mice, double transgenic mice highly express
HA-JDP2 in cardiomyocytes (15). To compare the tran-
scription of ATF3 in response to neuroendocrine stimula-
tion, control (driver mice, Wt) and JDP2-expressing
(double transgenic, JDP2) mice were injected with a
single dose of either angiotensin II (1.5mg/kg) or b-adre-
nergic agonist isoproterenol (2.5mg/kg). Mouse hearts
were collected 2h following injections and ATF3
expression was examined by western blot. Whereas vehicle
injected mice displayed a low basal level of ATF3 in both
genotypes, angiotensin II and isoproterenol injections
resulted in high ATF3 expression in the hearts of the con-
trol mice (Figure 5, top panel, lanes 1, 4 and 7). In con-
trast, JDP2 expressing mice displayed a barely detectable
induction of ATF3 protein (Figure 5, top panel, compare
lanes 4 and 7 with 5–6 and 8–9, respectively). JDP2 expres-
sion in double transgenic mice as well as a-tubulin loading
control are consistent with the ﬁnding that JDP2 over-
expression strongly suppressed the expression of the
ATF3 protein in response to angiotensin II and isoproter-
enol injections.
We wished to examine whether or not JDP2 protein
is capable in regulating the ATF3 promoter also under
physiological JDP2 expression level. Towards this end,
we used wild type and JDP2-KO mice injected with angio-
tensin II and followed the induction of ATF3 protein level
during a course of 2h. The induction of ATF3 protein
already appeared 30min following angiotensin II injection
into JDP2-KO mice (Figure 5B). On the other hand,
ATF3 induction in wild-type mice is apparent only 2h
following angiotensin II injection. Moreover, ATF3
expression level is higher in JDP2-KO mice 2h following
angiotensin II injection. Interestingly, c-Jun, a pre-
viously described JDP2 target gene (6), displayed a similar
proﬁle of expression as compared with ATF3 protein.
Namely, earlier induction time and higher expres-
sion level in response to angiotensin II stimulation
in JDP2-KO mice as compared with wild-type mice
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Figure 4. The extent of ATF3 induction to cellular stimulation is JDP2
dependent. (A) Western blot analysis with nuclear extract derived from
either wild-type MEF or JDP2-KO MEF cells. Cell lysate was prepared
at the indicated time from exponentially growing cells ( , lanes 1 and
6), 20% serum stimulated (serum, lanes 2–3 and 7–8) and 1mg/ml
thapsigargin treated (thapsigargin, lanes 4–5 and 9–10). The expression
level of ATF3 (top panel), JDP2 (middle panel) and a-tubulin (bottom
panel) was examined with the corresponding antibodies. (B) ChIP with
anti-JDP2 antibody with either wild-type or JDP2-KO MEF cells. Cells
were either untreated or treated with thapsigargin for 3h.
Formaldehyde ﬁxed sheared lysate was either precipitated directly
(total lanes 1 and 4) or precipitated with anti-JDP2 antibody.
Puriﬁed extracted DNA was ampliﬁed using appropriate primers cor-
responding to  246 to +25 genomic (expected size 271bp). The ampli-
ﬁed precipitated genomic DNA fragments were separated on 2%
agarose gel stained with ethidium bromide and visualized by UV light.
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Figure 5. ATF3 induction to humoral stimulation is dependent on
JDP2 expression level in the heart. (A) Western blot analysis with
cell lysate derived from hearts of MHCa-tTA transgenic mice (Wt.)
and JDP2-expressing double transgenic mice (JDP2) treated for 2h
with saline (vehicle, lanes 1–3), 1.5mg/kg angiotensin II (angiotensin
II, lanes 4–6) and 2.5mg/Kg isoproterenol (isoproterenol, lanes 7–9).
The expression levels of ATF3 (top panel), JDP2 (middle panel) and a-
tubulin (bottom panel) were examined with the corresponding antibo-
dies. (B) Western blot analysis with cell lysate derived from atria of
either wild-type mice or JDP2 KO mice treated with 1.5mg/kg angio-
tensin II for the indicated time. The expression level of ATF3 (top
panel), c-Jun (second top panel), JDP2 (third top panel) and
GAPDH (bottom panel) was examined with the corresponding
antibodies.
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unchanged following angiotensin II treatment and is
absent in heart derived from JDP2-KO mice.
JDP2 mediates ATF3response to liverinjury by carbon
tetrachloride, CCl4
To examine whether or not JDP2 controls ATF3 expres-
sion also following cellular stress insult in mice, we used a
single injection of CCl4. CCl4 is a known hepato-toxin that
triggers lipid peroxidation and liver damage (25). ATF3
protein was shown to be induced around the central veins
following CCl4 injection. Therefore, we followed ATF3
expression in the liver of JDP2 transgenic, JDP2 KO
and their respective control mice following a single injec-
tion of CCl4. To induce JDP2 transgene expression in the
liver, we crossed the LAP-tTA driver line with Tet-JDP2
transgene. Double transgenic mice highly express HA-
JDP2 speciﬁcally in the liver (Figure 6A, middle panel,
lanes 2 and 5–7). In wild-type mice, ATF3 is induced 4h
following CCl4 injection. In contrast, ATF3 expression is
barely detected in CCl4-injected JDP2 expressing mice
(Figure 6A, compare lanes 3–4 with 5–7).
To examine ATF3 expression following liver injury in
the absence of JDP2 protein, we injected JDP2-KO mice
and the respective C57BL/6 control mice with CCl4. The
ATF3 expression level in the liver was assessed at one and
3h following CCl4 injection (Figure 6B). JDP2-KO mice
display higher induction level of ATF3 protein at 3h fol-
lowing CCl4 injection (Figure 6B). Consistently, the two
other known JDP2 target genes, c-Jun and Chop10, are
induced to higher levels at 3h following CCl4 injection in
JDP2-KO mice. These results strongly suggest that alter-
ation in the JDP2 expression level determines the cellular
response towards multiple cellular stresses by controlling
the expression level of the immediate early gene ATF3.
DISCUSSION
ATF3 is an immediate early gene, thus its mRNA and
protein levels are highly induced following multiple cellu-
lar insults. In addition, overwhelming evidence from DNA
microarray added numerous non-stress signals that aﬀect
ATF3 expression (23). ATF3 expression is not cell type-
speciﬁc and represents part of the global cellular response
to environmental changes. Yet, the cellular fate in
response to environmental signals is dependent on the spa-
tial expression of the immediate early genes that are being
induced by the speciﬁc signal. Much information is avail-
able regarding the signaling pathways that are involved in
the induction of the ATF3 gene. These include the MAPK
cascades ERK, JNK and p38 (26) and multiple transcrip-
tion factors such as c-Jun/AP-1, ATF2 and CREB, as well
as others such as Myc, C/EBPb, Erg-1 and more (27,28).
In the current study, we have identiﬁed ATF3 as a target
gene for the AP-1 repressor protein, JDP2. Unlike the
known induction pathways, JDP2 is shown to be involved
in the cellular threshold response. Namely, the expression
of the ATF3 is dependent on the JDP2 expression level.
This was demonstrated in both JDP2 over-expression
models (Figure 1C) as well as with models in which
JDP2 expression is disrupted (Figures 4–6). In JDP2-KO
MEF cells a moderate increase in ATF3 protein basal
expression level is observed (Figure 4A). In contrast, in
non-treated JDP2-KO mice, ATF3 protein is undetectable
in the liver, heart, spleen and kidney (Figure 5 and 6 and
data not shown). Yet, we cannot exclude the possibility
that enhanced basal ATF3 protein expression in other
organs of JDP2-KO mice may be aﬀected. For example,
in the liver the basal protein expression levels of JDP2
target genes such as c-Jun, CHOP10 is higher in
JDP2-KO mice (Figure 6). On the other hand, no such
change in c-Jun expression level is observed in the heart
(Figure 5B). Previously it was shown, that HeLa cells
transiently transfected with JDP2 SiRNA resulted in a
higher basal level of CHOP10 mRNA (29).
Interestingly, in the heart of JDP2-KO mice, c-Jun dis-
played a similar kinetic as compared with ATF3 in
response to angiotensin II stimulation, i.e. an earlier
induction time and higher expression level as compared
with wild-type mice. In addition, the expression of
CHOP10 and c-Jun in response to CCl4 injection was
observed to follow ATF3 induction in the liver of
JDP2-KO mice (Figure 6B). Collectively, the data sug-
gests, that similar regulatory mechanisms may coordinate
the spatial expression of these genes. Unexpectedly, a tran-
sient increase in JDP2 protein expression level 1h follow-
ing CCl4 injection is observed. JDP2 is a ubiquitously
expressed protein and is not transcriptionaly regulated
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Figure 6. ATF3 induction in response to CCl4 is dependent on JDP2
expression level in the liver. (A) Western blot analysis with nuclear
extract derived from the liver of LAP-tTA transgenic mice (Wt.) and
JDP2 expressing double transgenic mice (JDP2) treated for 4h with
either olive oil (Vehicle) or 0.5ml/kg CCl4. The expression level of
ATF3 (top panel), JDP2 (middle panel) and a-tubulin (bottom panel)
was examined with the corresponding antibodies. (B) Western blot
analysis with nuclear cell lysate derived from the liver of either wild-
type mice or JDP2 KO mice treated with CCl4 0.5ml/kg for the indi-
cated hours. The expression levels of ATF3, c-Jun, Chop10, JDP2 and
a-tubulin were examined with the corresponding antibodies.
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hypothesize that the transient increase in JDP2 expression
may represent dissociated JDP2 protein from the chroma-
tin. This is consistent with reduced level of JDP2 that is
found bound to ATF3 promoter 3h following thapsigar-
gin stimulation (Figure 4B).
Promoter deletion mutants suggested that although the
ATF3 distal promoter harbors multiple CRE and TRE
elements between  1350 and  138, none of these were
regulated by JDP2. JDP2 is associated with CRE/ATF
site and a non-canonical site that are located within
100bp of the ATF3 proximal promoter region. So far,
only three JDP2 target genes were identiﬁed: c-Jun, C/
EBP d and CHOP10. Interestingly, JDP2 was found to
be associated with sequences located at the close proximity
of the promoters of these genes (2,6,11,29). The identiﬁ-
cation of additional JDP2 target genes will be important in
determining whether or not JDP2 binding to the proximal
promoter region is a general rule or just a coincidence.
The approach we took to identify JDP2 target genes by
microarray is clearly not comprehensive and additional
target genes will be recognized in the future. The criteria
we set for the identiﬁcation of a bona ﬁde JDP2 target
gene demanded a requisite of a basal level of expression
in the HeLa parental cell line. Luckily, HeLa cells are
relatively unique cell lines that display basal ATF3 protein
level even when grown in low serum medium (Figure 1C).
Typically, the basal level of ATF3 protein is below the
detectable levels in the cells. These results imply that
lack of activity of positive transcription factors in resting,
un-stimulated cells is responsible for the ATF3 low expres-
sion level.
The DNA elements within the ATF3 promoter, which
are JDP2-responsive, were identiﬁed as the ATF/CRE
consensus site and an ATF3 auto-regulatory element
located at  90 and  20 respectively. A detailed analysis
towards understanding the mechanism by which JDP2
dissociates from the promoter and allows ATF3 transcrip-
tion and subsequent auto-inhibition is currently under
way. Apparently, most of the signals that induce ATF3
expression may result in JDP2 phosphorylation. Since the
precise role of JDP2 phosphorylation is currently
unknown, it would be interesting to examine its role
using the knock-in approach in JDP2-KO MEF cells.
The regulation of ATF3 transcription may have impor-
tance in cancer pathophysiology, since ATF3 was shown
to have a dual role in carcinogenesis. On the one hand,
ATF3 was found to inhibit Ras-mediated transformation
(30). However, on the other hand, ATF3 was found to
protect breast cancer cells from stress-induced cell cycle
arrest and promote their cell motility and invasiveness
(31). In addition, ATF3 over-expression is a mediator of
cell proliferation in classical Hodgkin’s lymphoma (32).
Interestingly, JDP2 was found to inhibit cell cycle progres-
sion (9), Ras mediated cell transformation and tumor for-
mation in xenografts (18). In contrast, JDP2 was also
found to play a role in tumorogenesis under certain
genetic circumstances (19–21). Whether or not the role
of JDP2 in cancer progression is mediated via the regula-
tion of ATF3 transcription is yet to be determined.
Importantly, ATF3 was found to mediate the pro-apop-
totic eﬀects of anti-cancer drugs such curcumin (33) and
the PI3K inhibitor, LY294002 (34). Therefore, conditions
that would enhance ATF3 expression level, resulting in
potentiation of ATF3 pro-apoptotic activity in response
to anti cancer drugs, will be very useful in reaching higher
eﬃciency of the drugs with lower toxicity.
ACKNOWLEDGEMENTS
The authors wish to thank Ms Megumi Hirose, Ms
Satoko Masuzaki and Ms Aviva Cohen for their excellent
technical assistance. Thanks to Prof Tsonwin Hai,
for providing various reagents. A special thanks to
Dr Hiroshi Miyazaki who made this work possible.
FUNDING
Israeli Minister of Health [to A.A.]. Funding for open
access charge: A. Tufeld Cancer Research Fund.
Conﬂict of interest statement. None declared.
REFERENCES
1. Aronheim,A., Zandi,E., Hennemann,H., Elledge,S. and Karin,M.
(1997) Isolation of an AP-1 repressor by a novel method for
detecting protein-protein interactions. Mol. Cell Biol., 17,
3094–3102.
2. Jin,C., Ugai,H., Song,J., Murata,T., Nili,F., Sun,K., Horikoshi,M.
and Yokoyama,K.K. (2001) Identiﬁcation of mouse Jun dimeriza-
tion protein 2 as a novel repressor of ATF-2. FEBS Lett., 489,
34–41.
3. Broder,Y.C., Katz,S. and Aronheim,A. (1998) The Ras recruitment
system, a novel approach to the study of protein-protein interac-
tions. Curr. Biol., 8, 1121–1124.
4. Weidenfeld-Baranboim,K., Bitton-Worms,K. and Aronheim,A.
(2008) TRE-dependent transcription activation by JDP2-CHOP10
association. Nucleic Acids Res., 36, 3608–3619.
5. Kimura,M. (2008) IRF2-binding protein-1 is a JDP2 ubiquitin
ligase and an inhibitor of ATF2-dependent transcription. FEBS
Lett., 582, 2833–2837.
6. Jin,C., Li,H., Murata,T., Sun,K., Horikoshi,M., Chiu,R. and
Yokoyama,K.K. (2002) JDP2, a repressor of AP-1, recruits a
histone deacetylase 3 complex to inhibit the retinoic acid-induced
diﬀerentiation of F9 cells. Mol. Cell Biol., 22, 4815–4826.
7. Jin,C., Kato,K., Chimura,T., Yamasaki,T., Nakade,K., Murata,T.,
Li,H., Pan,J., Zhao,M., Sun,K. et al. (2006) Regulation of histone
acetylation and nucleosome assembly by transcription factor JDP2.
Nat. Struct. Mol. Biol., 13, 331–338.
8. Katz,S., Heinrich,R. and Aronheim,A. (2001) The AP-1 repressor,
JDP2, is a bona ﬁde substrate for the c-Jun N- terminal kinase.
FEBS Lett., 506, 196–200.
9. Ostrovsky,O., Bengal,E. and Aronheim,A. (2002) Induction of
terminal diﬀerentiation by the c-Jun dimerization protein JDP2 in
C2 myoblasts and rhabdomyosarcoma cells. J. Biol. Chem., 277,
40043–40054.
10. Kawaida,R., Ohtsuka,T., Okutsu,J., Takahashi,T., Kadono,Y.,
Oda,H., Hikita,A., Nakamura,K., Tanaka,S. and Furukawa,H.
(2003) Jun dimerization protein 2 (JDP2), a member of the AP-1
family of transcription factor, mediates osteoclast diﬀerentiation
induced by RANKL. J. Exp. Med., 197, 1029–1035.
11. Nakade,K., Pan,J., Yoshiki,A., Ugai,H., Kimura,M., Liu,B., Li,H.,
Obata,Y., Iwama,M., Itohara,S. et al. (2007) JDP2 suppresses
adipocyte diﬀerentiation by regulating histone acetylation. Cell
death Diﬀ., 14, 1398–1405.
2202 Nucleic Acids Research, 2009, Vol. 37,No. 712. Hai,T., Wolfgang,C.D., Marsee,D.K., Allen,A.E. and
Sivaprasad,U. (1999) ATF3 and stress responses. Gene Exp., 7,
321–335.
13. Hai,T. and Curran,T. (1991) Cross-family dimerization of
transcription factors Fos/Jun and ATF/CREB alters DNA binding
speciﬁcity. Proc. Natl Acad. Sci. USA, 88, 3720–3724.
14. Kehat,I., Heinrich,R., Ben-Izhak,O., Miyazaki,H., Gutkind,J.S. and
Aronheim,A. (2006) Inhibition of basic leucine zipper transcription
is a major mediator of atrial dilatation. Cardiovasc. Res., 70,
543–554.
15. Kehat,I., Hasin,T. and Aronheim,A. (2006) The role of basic
leucine zipper protein-mediated transcription in physiological
and pathological myocardial hypertrophy. Ann. N Y Acad. Sci.,
1080, 97–109.
16. Piu,F., Aronheim,A., Katz,S. and Karin,M. (2001) AP-1 repressor
protein JDP-2: inhibition of UV-mediated apoptosis through p53
down-regulation. Mol. Cell Biol., 21, 3012–3024.
17. Katz,S. and Aronheim,A. (2002) Diﬀerential targeting of the stress
mitogen-activated protein kinases to the c-Jun dimerization protein
2. Biochem. J., 368, 939–945.
18. Heinrich,R., Livne,E., Ben-Izhak,O. and Aronheim,A. (2004) The
c-Jun Dimerization Protein 2 Inhibits Cell Transformation and Acts
as a Tumor Suppressor Gene. J. Biol. Chem., 279, 5708–5715.
19. Rasmussen,M.H., Sorensen,A.B., Morris,D.W., Dutra,J.C.,
Engelhard,E.K., Wang,C.L., Schmidt,J. and Pedersen,F.S. (2005)
Tumor model-speciﬁc proviral insertional mutagenesis of the
Fos/Jdp2/Batf locus. Virol., 337, 353–364.
20. Hwang,H.C., Martins,C.P., Bronkhorst,Y., Randel,E., Berns,A.,
Fero,M. and Clurman,B.E. (2002) Identiﬁcation of oncogenes
collaborating with p27Kip1 loss by insertional mutagenesis and
high-throughput insertion site analysis. Proc. Natl Acad. Sci. USA,
99, 11293–11298.
21. Stewart,M., Mackay,N., Hanlon,L., Blyth,K., Scobie,L.,
Cameron,E. and Neil,J.C. (2007) Insertional mutagenesis reveals
progression genes and checkpoints in MYC/Runx2 lymphomas.
Cancer Res., 67, 5126–5133.
22. Wolfgang,C.D., Liang,G., Okamoto,Y., Allen,A.E. and Hai,T.
(2000) Transcriptional autorepression of the stress-inducible gene
ATF3. J. Biol. Chem., 275, 16865–16870.
23. Hai,T. (ed.) (2006) The ATF Transcription Factors in Cellular
Adaptive Responses. Higher Education Press, Beijing, People’s
Republic of China and Springer-Verlag, NY.
24. Kistner,A., Gossen,M., Zimmermann,F., Jerecic,J., Ullmer,C.,
Lubbert,H. and Bujard,H. (1996) Doxycycline-mediated quantita-
tive and tissue-speciﬁc control of gene expression in transgenic mice.
Proc. Natl Acad. Sci. USA, 93, 10933–10938.
25. Palmes,D. and Spiegel,H.U. (2004) Animal models of liver regen-
eration. Biomaterials, 25, 1601–1611.
26. Lu,D., Chen,J. and Hai,T. (2007) The regulation of ATF3
gene expression by mitogen-activated protein kinases. Biochem. J.,
401, 559–567.
27. Tamura,K., Hua,B., Adachi,S., Guney,I., Kawauchi,J.,
Morioka,M., Tamamori-Adachi,M., Tanaka,Y., Nakabeppu,Y.,
Sunamori,M. et al. (2005) Stress response gene ATF3 is a target of
c-myc in serum-induced cell proliferation. EMBO J., 24, 2590–2601.
28. Huo,J.S., McEachin,R.C., Cui,T.X., Duggal,N.K., Hai,T.,
States,D.J. and Schwartz,J. (2006) Proﬁles of growth hormone
(GH)-regulated genes reveal time-dependent responses and identify
a mechanism for regulation of activating transcription factor 3 by
GH. J. Biol. Chem., 281, 4132–4141.
29. Cherasse,Y., Chaveroux,C., Jousse,C., Maurin,A.C., Carraro,V.,
Parry,L., Fafournoux,P. and Bruhat,A. (2008) Role of the repressor
JDP2 in the amino acid-regulated transcription of CHOP. FEBS
Lett., 582, 1537–1541.
30. Lu,D., Wolfgang,C.D. and Hai,T. (2006) Activating transcription
factor 3, a stress-inducible gene, suppresses Ras-stimulated tumor-
igenesis. J. Biol. Chem., 281, 10473–10481.
31. Yin,X., Dewille,J.W. and Hai,T. (2008) A potential dichotomous
role of ATF3, an adaptive-response gene, in cancer development.
Oncogene, 27, 2118–2127.
32. Janz,M., Hummel,M., Truss,M., Wollert-Wulf,B., Mathas,S.,
Johrens,K., Hagemeier,C., Bommert,K., Stein,H., Dorken,B. et al.
(2006) Classical Hodgkin lymphoma is characterized by high
constitutive expression of activating transcription factor 3 (ATF3),
which promotes viability of Hodgkin/Reed-Sternberg cells. Blood,
107, 2536–2539.
33. Yan,C., Jamaluddin,M.S., Aggarwal,B., Myers,J. and Boyd,D.D.
(2005) Gene expression proﬁling identiﬁes activating transcription
factor 3 as a novel contributor to the proapoptotic eﬀect of
curcumin. Mol. Cancer Therap., 4, 233–241.
34. Yamaguchi,K., Lee,S.H., Kim,J.S., Wimalasena,J., Kitajima,S. and
Baek,S.J. (2006) Activating transcription factor 3 and early
growth response 1 are the novel targets of LY294002 in a
phosphatidylinositol 3-kinase-independent pathway. Cancer Res.,
66, 2376–2384.
Nucleic Acids Research,2009, Vol.37, No. 7 2203